Treatment Satisfaction in Patients with Hidradenitis Suppurativa: A Real-World Survey from the EU5 and USA
These real-world data suggest a high disease burden and potential undertreatment in patients with HS. Patients received multiple treatments, and a notable proportion underwent surgery. Robustly integrating the patient voice in HS treatment decisions may lead to better outcomes and improved treatment satisfaction.
Authors
- Torben Kasparek
- Vincenzo Bettoli (ORCID: https://orcid.org/0000-0002-2760-4600)
- Emily Coak
- Elisa Muscianisi (ORCID: https://orcid.org/0000-0002-2795-2744)
- John R Ingram (ORCID: https://orcid.org/0000-0002-5257-1142)
- Antonio Martorell (ORCID: https://orcid.org/0000-0003-1378-1590)
- Jasmine I. Espy
- Hayley Wallinger
- Alexa B. Kimball (ORCID: https://orcid.org/0000-0001-9405-0479)
- Isabel Truman (ORCID: https://orcid.org/0000-0002-6055-2902)
- Craig Richardson
- A. Villani (ORCID: https://orcid.org/0000-0002-3067-807X)
- Georgios Kokolakis
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Novartis (Switzerland) (CH)
- Beth Israel Deaconess Medical Center (US)
- University of Ferrara (IT)
- Humboldt-Universität zu Berlin (DE)
- Adelphi Group (United Kingdom) (GB)
- Hospices Civils de Lyon (FR)
- Novartis (United States) (US)
- Hospital de Manises (ES)
- Hôpital Edouard Herriot (FR)
- Hidradenitis Suppurativa Foundation (US)
- Cardiff University (GB)
Publication Details
- Journal
- Dermatology
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1159/000542343
- Citations
- 4
- Primary Topic
- Hidradenitis Suppurativa and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.14
Funders
- Novartis Pharma
- Novartis Pharmaceuticals UK Limited